Northfield Laboratories, Inc. (NASDAQ: NFLD), a leading developer of oxygen-carrying red blood cell substitute, is focused on addressing the need for the treatment of life-threatening blood loss when oxygen-carrying fluid is required and red blood cells are not available. The company’s PolyHeme product restores lost blood volume and hemoglobin levels and is able to be administered rapidly in massive amounts. For further information, visit the Company’s web site at www.northfieldlabs.com.
- 17 years ago
QualityStocks
Northfield Laboratories, Inc. (NASDAQ: NFLD)
Tags Rodman & Renshaw
Related Post
-
Renewal Fuels Inc. (RNWF) Discusses Ambitious Fusion Reactor Plan, Business Model and Strategy, on Stock2Me Podcast
The company aims to deliver a 100-megawatt fusion reactor in 2026, with an earlier 5-MW…
-
Navigating a Rapidly Evolving Technology Landscape: Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and the Trump Administration’s Push to Secure Domestic Supplies of Critical Minerals
Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include…
-
SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Explores GPS Alternatives in Evolving Electronic Warfare Landscape
Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. The…